Newer Advances in the Management of Atopic Dermatitis and Role of PDE4 Inhibitor

Speciality: Dermatology


Speaker:

Dr. V K Somani - Moderator | MBBS,MD,D.D

Dr. Manoj Parekh | MBBS,DDVL,FAAD

Dr. Carol Fernandes FERNANDES (MASCARENHAS) | CHIEF CONSULTANT & HEAD

Dr. A K Lahiry | MD,DD

Dr. D Indira | MD Associate Professor of Derm.,/DVL

Description:

A warm welcome to all the medical professionals in this interesting session on newer advances in the management of atopic dermatitis and role of PDE4 inhibitor.
Recent advances in the management of atopic dermatitis (AD) have introduced novel therapies targeting the underlying immune pathways involved in the disease. Traditional treatments, such as topical corticosteroids and immunosuppressants, while effective, can have limitations in long-term use due to side effects. Emerging biologics and small-molecule therapies offer more precise targeting of inflammation, improving outcomes for patients with moderate to severe AD.
One of the newer advances includes the use of PDE4 inhibitors, such as crisaborole, which selectively inhibit the enzyme phosphodiesterase 4 (PDE4). By blocking PDE4, these inhibitors reduce the production of pro-inflammatory cytokines, helping to control inflammation in the skin. PDE4 inhibitors offer an alternative for patients seeking non-steroidal topical treatments, providing effective symptom relief while minimizing the side effects associated with corticosteroids.
Therefore, get an overall knowledge on newer advances in the management of atopic dermatitis and role of PDE4 inhibitor. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions.
 

See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study opens up possibility of bespoke prostate cancer treatment

2.

Why Encouragement May Not Improve Motivation in Depression

3.

Study Finds Actionable Mutations in Brain Mets of Breast Cancer Patients

4.

A person's susceptibility to papillary thyroid cancer may be determined by variations in telomere lengthening genes.

5.

Pirtobrutinib May Be Beneficial in Follicular Lymphoma with Severe Pretreatment.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot